ArticleMolecular oncology2025

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer.

Koh Furugaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.